AZD 1419

Drug Profile

AZD 1419

Alternative Names: AZ-1419; AZD-1419; Second-generation TLR-9 agonist - AstraZeneca/Dynavax

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Dynavax Technologies
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Asthma in USA (Inhalation)
  • 01 Oct 2016 Phase-II clinical trials in Asthma in Denmark (Inhalation) (NCT02898662)
  • 19 Jan 2016 Dynavax and AstraZeneca amend research agreement; AstraZeneca will now conduct planned phase IIa trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top